Kong ZZ, Zhang L. Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report. World J Clin Cases 2022; 10(18): 6241-6246 [PMID: 35949855 DOI: 10.12998/wjcc.v10.i18.6241]
Corresponding Author of This Article
Lu Zhang, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Post Road, Shangcheng District, Hangzhou 310000, Zhejiang Province, China. zl06302021@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2022; 10(18): 6241-6246 Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6241
Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report
Zhen-Zhen Kong, Lu Zhang
Zhen-Zhen Kong, Lu Zhang, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China
Author contributions: Kong ZZ was involved in writing the article; Zhang L was involved in the conception of the study; all authors read and approved the final manuscript.
Supported byZhejiang Provincial Department of Health Clinical Research Application Project, No. 2022KY924; and General Project of Zhejiang Provincial Department of Health, No. 2021KY835.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu Zhang, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Post Road, Shangcheng District, Hangzhou 310000, Zhejiang Province, China. zl06302021@163.com
Received: November 30, 2021 Peer-review started: November 30, 2021 First decision: March 11, 2022 Revised: March 16, 2022 Accepted: April 27, 2022 Article in press: April 27, 2022 Published online: June 26, 2022 Processing time: 198 Days and 14.1 Hours
Abstract
BACKGROUND
At present, cases of esophageal neuroendocrine tumors combined with cardia adenocarcinoma are extremely rare worldwide, and there are no clinical reports. Herein, we describe such a case for clinical reference.
CASE SUMMARY
The presence of cardia cancer and esophageal neuroendocrine tumors in a single patient has not yet been reported. The patient in this case underwent prompt endoscopic treatment and additional surgical resection. Pathology revealed the following: The distance between the cardia cancer and the esophageal neuroendocrine tumors was small, approximately 3 mm. Vascular invasion was observed. The esophageal neuroendocrine tumor was determined to be grade G3. According to the treatment guidelines, after the patient received an explanation of their condition, additional surgical procedures were provided in a timely manner. Early detection and early treatment can successfully prolong survival and improve the quality of life of patients.
CONCLUSION
Early detection and early treatment can successfully prolong survival and improve the quality of life of such patients.
Core Tip: Cases of esophageal neuroendocrine tumors combined with moderately differentiated gastric cardia adenocarcinoma are very rare. Pathology is the gold standard for diagnosis. Endoscopy and additional surgical resection proved to be successful in our case. Early detection and early treatment are both of great significance to the life and health of patients. Considering the successful resection of this case, we provide this case report to serve as a clinical reference.
